Trending...
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 196
- A Letter From the Tacoma City Council to the Sound Transit Board
- Tacoma City Council Member Kristina Walker to Share Sound Transit Updates During March 31 Study Session
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global urinary incontinence treatment drugs market is estimated to be valued at US$ 4,180.6 million in 2020 and is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027).
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
Related Market Intelligence Reports:
More on Washingtoner
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Key Trends and Analysis:
The global urinary incontinence treatment drugs market is expected to witness significant growth, owing to increasing prevalence of urinary incontinence. According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence of which, 303 million were women.
According to the American Urological Association (AUA), in 2013, around 60%-70% of men and women suffered from urinary incontinence in the U.S.
For instance, according to American Urological Association (AUA) 2017 report, more than 200 million people worldwide were affected with stress urinary incontinence (SUI) in 2017, which can seriously affect the quality of life of both men and women. As a disease whose prevalence is related to advancing age, it affects more women than men with an approximate ratio of 3: 1.
Approval of urinary incontinence treatment drugs is also expected to drive growth of the global urinary incontinence treatment drugs market. For instance, in October 2020, Zydus Cadila received final approval from the US Food and Drug Administration (FDA) to market Solifenacin Succinate tablets, used for the treatment of overactive bladder.
Buy-Now this Research Report for detailed market insights: https://www.coherentmarketinsights.com/insight/buy-now/4400
More on Washingtoner
- Congressional Roundtable Exposes Mental Health Crisis: More Spending and Treatment, Worse Results – CCHR Demands Accountability
- Dental Implants in Everett, WA: 19th Avenue Dental Offers Permanent Tooth Replacement Solutions
- Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking
- NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection
- PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain
Key Market Takeaways:
The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.8% during the forecast period (2020-2027), owing to the increasing approval of drugs from regulatory authorities. For instance, in June 2019, Lupin limited announced that it received tentative approval for its Mirabegron Extended Release (ER) Tablets, 25 mg and 50 mg, from the U.S. Food and Drug Administration (FDA), to market a generic version of Myrbetriq Extended Release Tablets, 25 mg and 50 mg, of Astellas Pharma Global Development Inc. (Astellas), which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Competitive Landscape:
Key players operating in the global urinary incontinence treatment drugs market include Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Sanofi S.A.
Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/4400
Market Segmentation:
- Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type:
- Urge Incontinence
- Stress Incontinence
- Over-flow Incontinence
- Mixed Incontinence
- Other Type
- Global Urinary Incontinence Treatment Drugs Market, By Drug Class:
- Anticholinergic/Antispasmodic Agents
- Skeletal Muscle Relaxants
- Antidepressants
- Alpha Blockers
- Topical Estrogens
- Others
- Global Urinary Incontinence Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Urinary Incontinence Treatment Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
More on Washingtoner
- Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
- Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
- UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
- Ashikaga Flower Park's "Great Wisteria Festival 2026"
- Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
Urinary Incontinence Treatment Devices Market, by Product (Urinary Catheters, Electrical Stimulation Devices, Artificial Urinary Sphincters, Wearable Devices, Slings (Male Slings and Female Slings), and Other Devices), by Category (Internal Urinary Incontinence Devices and External Urinary Incontinence Devices), by Incontinence (Stress Incontinence, Urge Incontinence, Overflow Incontinence, and Functional Incontinence), by End User (Clinics, Hospitals, Ambulatory surgical centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019–2026
Read more: https://www.coherentmarketinsights.com/ongoing-insight/urinary-incontinence-treatment-devices-market-2892
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
0 Comments
Latest on Washingtoner
- Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
- Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
- Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
- Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
- The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
- Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
- A Letter From the Tacoma City Council to the Sound Transit Board
- Tacoma: City Council Approves Contract, Officially Appointing Hyun Kim as City Manager
- Tacoma: Homicide Investigation – 3400 Block South 19th Street
- L2 Aviation Earns FAA STC for Thales AVIATOR 200S for Boeing 777
- Women-Owned Business Platform SmartPath Launches to Help Entrepreneurs Build with Confidence
- FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
- City of Spokane Celebrates Return of Spokane Gives
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
- AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
- Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)